Why Is VERACYTE INC (VCYT) Stock Up Today?

Veracyte Inc stock fell 3.17% to $44.85 in early trading as Canaccord cut its price target to $50 based on the company’s revenue outlook. The move reflects a shift in analyst expectations for the biotechnology firm, which has seen recent gains in revenue but faces ongoing pressure from sell-side actions. The stock has lost 20.2% over the past eight sessions amid mixed market sentiment and insider selling activity.

What Happened

Canaccord Genuity lowered its price target for Veracyte to $50 while maintaining a Hold rating. This downgrade came after the company raised its full-year 2026 sales guidance to between $590 million and $596 million, exceeding current estimates. Despite this positive revenue outlook, the stock fell as the revised target signaled reduced confidence in near-term upside. Meanwhile, Needham maintained a Buy rating and raised its own price target to $69, offering a counterpoint to the bearish sentiment. Veracyte also reported Q2 adjusted earnings of $0.54 per share, beating estimates, and revenue of $150.321 million, which also exceeded forecasts. However, the stock’s performance appears to have been more influenced by the downgrade from Canaccord than the strong quarterly results.

What The Data Shows

Over the past eight trading sessions, Veracyte’s stock has declined from $58.01 to $46.32, a significant pullback. The stock is currently trading within its 52-week range of $22.92 to $60.91. Insiders have sold a total of $9.7 million worth of shares in the last 90 days, with the most recent transaction occurring on June 22. No insider purchases were recorded during this period. Congressional disclosures show Rep. Gilbert Cisneros made two small purchases of VCYT shares in February and March, but no sales were reported.

What To Watch

Investors should monitor the company’s next earnings report, if scheduled, as well as any further analyst activity. The divergence in analyst ratings between Canaccord and Needham highlights the need for continued coverage breadth to assess the stock’s trajectory.